MECP2-related severe neonatal encephalopathy

MECP2-related severe neonatal encephalopathy is an extremely rare and devastating neurological disorder caused by mutations in the MECP2 (methyl-CpG binding protein 2) gene, located on the X chromosome. This condition predominantly affects males and presents at birth or within the first weeks of life with severe encephalopathy, distinguishing it from the more commonly known Rett syndrome, which primarily affects females. The disorder is characterized by profound intellectual disability, severe hypotonia, breathing abnormalities (including central hypoventilation and respiratory failure), absent or minimal psychomotor development, and seizures. Microcephaly (reflected in the ICD-10 code Q02) may be present or develop postnatally. Affected infants often exhibit poor feeding, abnormal movements, and a markedly reduced level of consciousness. The condition primarily affects the central nervous system, with the brain being the most severely impacted organ. Neurological dysfunction leads to widespread impairment of motor, cognitive, and autonomic functions. Many affected males experience life-threatening respiratory insufficiency requiring ventilatory support. Additional features may include gastrointestinal dysmotility and cardiac rhythm abnormalities. The prognosis is generally very poor, with many affected individuals dying in infancy or early childhood. There is currently no cure or disease-modifying treatment for MECP2-related severe neonatal encephalopathy. Management is entirely supportive and symptomatic, focusing on seizure control with antiepileptic medications, respiratory support (which may include mechanical ventilation), nutritional support through gastrostomy tube feeding, and physical therapy to manage spasticity and contractures. Genetic counseling is important for affected families, as the condition may arise de novo or be inherited from a carrier mother.

Common questions about MECP2-related severe neonatal encephalopathy